Effects of ethinylestradiol and levonorgestrel on morphology, ultrastructure and histoenzymatic activity of rat kidney.
Sexually mature female Wistar rats were given daily intragastric doses of ethinylestradiol (EE) and levonorgestrel (LE) used normally in women: (1) 0.03 mg EE and 0.05 mg LE; (2) 0.04 mg EE and 0.075 mg LE; (3) 0.03 mg EE and 0.125 mg LE. All groups were treated for 6 months in 5-day cycles (four-day treatment with a one-day break), i.e. for 36 sexual cycles. In rat kidneys, the activity of succinic dehydrogenase, NADPH-tetrazolium reductase, Mg(2+)-ATPase and alkaline phosphatase were decreased, while those of lactate dehydrogenase, acid phosphatase and glucose-6-phosphatase were enhanced. We have found a correlation between enzymatic changes and ultrastructural changes in epithelial renal cells. These changes may reflect: (1) inhibited oxidative processes associated with the mitochondrial and microsomal systems of electron transport; (2) a compensatory increase in anaerobic processes; (3) increased glyconeogenesis; (4) inhibited transport processes and increased cellular catabolism. The kidney cortex and medulla did not show any significant morphological changes after 6 months of treatment. The study has shown that EE/LE combinations produce histochemical and ultrastructural changes in the kidney, which are dependent on the doses of gestagens.
Nowaczyk-Dura
G
G
Second Department of Histology and Embryology, Silesian Medical Academy, Katowice, Poland.
Czekaj
P
P
D000135:Acid Phosphatase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D017301:Ca(2+) Mg(2+)-ATPase / Q000378:metabolism; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage / Q000009:adverse effects*; D004847:Epithelial Cells / Q000648:ultrastructure; D045166:Estradiol Congeners / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D006651:Histocytochemistry; D007668:Kidney / Q000187:drug effects / Q000201:enzymology* / Q000648:ultrastructure*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects*; D008854:Microscopy, Electron; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D045167:Progesterone Congeners / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D013385:Succinate Dehydrogenase / Q000378:metabolism
D003280:Contraceptives, Oral, Synthetic; D045166:Estradiol Congeners; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; D007770:L-Lactate Dehydrogenase; D013385:Succinate Dehydrogenase; C021848:NADPH-tetrazolium reductase; D009251:NADPH-Ferrihemoprotein Reductase; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D005952:Glucose-6-Phosphatase; D017301:Ca(2+) Mg(2+)-ATPase